Medicenna Therapeutics (TSE:MDNA) Hits New 12-Month Low – What’s Next?

Medicenna Therapeutics Corp. (TSE:MDNA)’s share price reached a new 52-week low on Friday . The stock traded as low as C$1.01 and last traded at C$1.03, with a volume of 30290 shares traded. The stock had previously closed at C$1.01.

Medicenna Therapeutics Stock Performance

The firm’s 50-day moving average price is C$1.38 and its two-hundred day moving average price is C$1.81. The firm has a market capitalization of C$77.81 million, a PE ratio of -2.86 and a beta of 1.21. The company has a quick ratio of 4.65, a current ratio of 11.40 and a debt-to-equity ratio of 0.88.

Insider Transactions at Medicenna Therapeutics

In related news, Senior Officer David Hyman acquired 20,000 shares of the company’s stock in a transaction on Thursday, January 9th. The shares were purchased at an average price of C$1.45 per share, for a total transaction of C$29,000.00. 22.57% of the stock is currently owned by insiders.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.